This inventor holds 5 USPTO granted patents and 1 published patent application and 6 EPO patents. Top assignee: Basf Se Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Martin John McLaughlin: Innovator in Pharmaceutical Chemistry
Introduction: Martin John McLaughlin is a notable inventor based in Liestal, Switzerland. He is currently associated with BASF SE Corporation, where he contributes to advancements in pharmaceutical chemistry. Despite having no granted patents, his work in the field is significant and reflects his dedication to innovation.
Latest Patent Applications: Martin John McLaughlin has filed several patent applications, including:
1. **METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE BY HYDROGENATION OF THE 2-OXO DERIVATIVE IN THE PRESENCE OF A CHIRAL TRANSITION METAL CATALYST** - This invention relates to a method for preparing an enantiomerically enriched form of the compound by hydrogenation in the presence of a chiral transition metal catalyst.
2. **METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE** - This application focuses on preparing the compound or its tautomer/enantiomerically enriched forms, and its use as an intermediate in the preparation of specific thiazolo[3,2-a]pyrimidinium compounds.
Conclusion: Martin John McLaughlin's contributions to pharmaceutical chemistry through his innovative patent applications highlight his role as a dedicated inventor in the field. His work continues to pave the way for advancements in drug development and synthesis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile